As Anaptysbio pushes forward with its new biological, the cost watchdog Icer questions the prices of products from Glaxosmithkline, Astrazeneca and Teva.
A non-profit partnership of 500 hospitals wants to deliver its first generic drugs in 2019, lowering prices and stabilising supplies.
Balloons are as good as stents, but it can be hard to get cardiologists to change their habits.
Over industry objections, a Medicare panel endorses patient symptom reporting tools that could lower payments for drugs with a high side-effect burden.
To determine whether Medicare covers CAR-T it might soon be important to find out how patients feel.
Pharma sector pushes back against a programme that mandates cheaper prices for hospitals serving the poor.
Biopharma might be getting the pricing controls that it tried to stop.
If investors have visions of Luxturna-like prices they might need to blink and look again.
Medicare Advantage plans have been cleared to seek cheaper alternatives for biologicals beginning next year.